The FAERS Potential Signals of Serious Risks/New Safety Information listed Turalio (pexidartinib) with Photosensitivity reaction as a potential signal on their January - March 2023 listing.
Analyzing the FAERS data up to 2023 Q3, the PRR for Photosensitivity reaction is greater than 2 when comparing pexidartinib within its ATC groups OTHER PROTEIN KINASE INHIBITORS, PROTEIN KINASE INHIBITORS, ANTINEOPLASTIC AGENTS and ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS.
PEXIDARTINIB ATCs | PRR | MGPS | BCPN | ROR | CHISQ |
|---|---|---|---|---|---|
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | 21.96667 | 21.53373 | 48.23551 | 22.01752 | 274.4163 |
ANTINEOPLASTIC AGENTS | 20.18732 | 19.79113 | 45.75302 | 20.29312 | 250.1133 |
PROTEIN KINASE INHIBITORS | 14.16701 | 13.89513 | 42.75239 | 14.34042 | 167.9458 |
OTHER PROTEIN KINASE INHIBITORS | 16.14803 | 15.83524 | 38.37115 | 17.17253 | 195.614 |
Photosensitivity reaction is included in 2 SMQs (Hypersensitivity and Systemic lupus erythematosus) under the broad scope category. There are no other adverse events reported for pexidartinib under the HLT Photosensitivity and photodermatosis conditions. Further analysis is required to confirm the potential signal.
Comments